ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 20th Annual Healthcare Conference

• Press Release
• Source: ImmunoGen, Inc.
• On 6:30 am EDT, Tuesday October 27, 2009

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN - News), a biotechnology company that develops targeted anticancer products, today announced that its presentation at the Oppenheimer 20^th Annual Healthcare Conference will be webcast live. The presentation is scheduled to begin at 1:00 p.m. ET on November 3, 2009, and will be given at the Waldorf=Astoria hotel in New York. The presentation will provide an update on the Company.

Related Quotes

Symbol	Price	Change
IMGN	8.36	+0.30

{"s" : "imgn","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The webcast can be accessed through the Investor Information section of the ImmunoGen website (www.immunogen.com). Following the live webcast, a replay of the presentation will be available at the same location until November 10, 2009.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen’s proprietary cancer-cell killing agents specifically to cancer targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations
and Corporate Communications
info@immunogen.com